The tweet was deleted by the author.
But we saved everything 🙂.
Phathom Pharmaceuticals has unveiled new research findings indicating that the use of GLP-1s in individuals with Type 2 Diabetes is associated with higher rates of gastroesophageal reflux disease (GERD) and related complications, compared to the use of SGLT-2 inhibitors.
This study is being highlighted during GERD Awareness Week to deepen the understanding of GERD and its implications on health. The data stems from real-world observations and promises to contribute significantly to the medical community's appreciation of the nuanced effects of diabetes medications on digestive health.